A label-free biosensor assay for botulinum neurotoxin B in food and human serum.

Botulinum neurotoxins (BoNTs) are among the most toxic substances known. Surveillance and diagnostics require methods for rapid detection of BoNTs in complex media such as foodstuffs and human serum. We have developed in vitro assays to specifically detect the protease activity of botulinum neurotoxin B (BoNT/B) on a time scale of minutes. Cleavage of the BoNT/B substrate VAMP2, a membrane SNARE protein associated with synaptic vesicles, was monitored using real-time surface plasmon resonance to measure vesicle capture by specific antibodies coupled to microchips. The assay is functional in low-ionic-strength buffers and stable over a wide range of pH values (5.5-9.0). Endoproteolytic cleavage of VAMP2 was detected in 10 min with 2 pM native BoNT/B holotoxin. Contamination of liquid food products such as carrot juice, apple juice, and milk with low picomolar amounts of BoNT/B was revealed within 3h. BoNT/B activity was detected in sera from patients with type B botulism but not in healthy controls or patients with other neurological diseases. This robust, sensitive, and rapid protein chip assay is appropriate for monitoring BoNT/B in food products and diagnostic tests for type B botulism and could replace the current in vivo mouse bioassay.

[1]  G. Schiavo,et al.  VAMP/synaptobrevin cleavage by tetanus and botulinum neurotoxins is strongly enhanced by acidic liposomes , 2003, FEBS letters.

[2]  C. Frassoni,et al.  Entering neurons: botulinum toxins and synaptic vesicle recycling , 2006, EMBO reports.

[3]  K. Weisser,et al.  An in vitro assay for detection of tetanus neurotoxin activity: using antibodies for recognizing the proteolytically generated cleavage product. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[4]  P. Dunnigan,et al.  Development of an In Vitro Bioassay for Clostridium botulinum Type B Neurotoxin in Foods That Is More Sensitive than the Mouse Bioassay , 1999, Applied and Environmental Microbiology.

[5]  H. Hines,et al.  Use of a Recombinant Fluorescent Substrate with Cleavage Sites for All Botulinum Neurotoxins in High-Throughput Screening of Natural Product Extracts for Inhibitors of Serotypes A, B, and E , 2007, Applied and Environmental Microbiology.

[6]  Philip K. Russell,et al.  Botulinum toxin as a biological weapon: medical and public health management. , 2001, JAMA.

[7]  D. Gill,et al.  Bacterial toxins: a table of lethal amounts , 1982, Microbiological reviews.

[8]  G. Sakaguchi.  Clostridium botulinum toxins. , 1982, Pharmacology & therapeutics.

[9]  C. Shone,et al.  Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin. , 1994, European journal of biochemistry.

[10]  R. Fagan,et al.  Persistence of botulinum toxin in patients' serum: Alaska, 1959-2007. , 2009, The Journal of infectious diseases.

[11]  C. Lévêque,et al.  Synaptic vesicle chips to assay botulinum neurotoxins. , 2005, The Biochemical journal.

[12]  K. Janda,et al.  Selection and characterization of a human monoclonal neutralizing antibody for Clostridium Botulinum neurotoxin serotype B. , 2009, Bioorganic & medicinal chemistry letters.

[13]  C. Lévêque,et al.  A protein chip membrane-capture assay for botulinum neurotoxin activity. , 2008, Toxicology and applied pharmacology.

[14]  Hannu Korkeala,et al.  Laboratory Diagnostics of Botulism , 2006, Clinical Microbiology Reviews.

[15]  Suzanne R. Kalb,et al.  The use of Endopep-MS for the detection of botulinum toxins A, B, E, and F in serum and stool samples. , 2006, Analytical biochemistry.

[16]  J. Dolly,et al.  Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. , 1994, Biochemistry.

[17]  S. Dessain,et al.  Neutralization of Botulinum Neurotoxin by a Human Monoclonal Antibody Specific for the Catalytic Light Chain , 2008, PloS one.

[18]  A. Chenal,et al.  Interaction between the two subdomains of the C‐terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies , 2004, FEBS letters.

[19]  S. Tzipori,et al.  Efficient Serum Clearance of Botulinum Neurotoxin Achieved Using a Pool of Small Antitoxin Binding Agents , 2009, Infection and Immunity.

[20]  Suzanne R. Kalb,et al.  From the mouse to the mass spectrometer: detection and differentiation of the endoproteinase activities of botulinum neurotoxins A-G by mass spectrometry. , 2005, Analytical chemistry.

[21]  D. Sesardic,et al.  Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. , 2008, Journal of immunological methods.

[22]  D. Vugia,et al.  Sensitivity of mouse bioassay in clinical wound botulism. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  T. Haltia,et al.  Forces and factors that contribute to the structural stability of membrane proteins. , 1995, Biochimica et biophysica acta.

[24]  Leonard A. Smith,et al.  Expression, purification, and characterization of Clostridium botulinum type B light chain. , 2006, Protein expression and purification.

[25]  Andrea M. Stahl,et al.  Gaining ground: assays for therapeutics against botulinum neurotoxin. , 2010, Trends in microbiology.

[26]  C. Lévêque,et al.  Real time analysis of intact organelles using surface plasmon resonance. , 2004, Analytical biochemistry.